Long post sorry - BUT ...I just jumped into TSOI last week and I am going to stay here for a while. Stem Cell Science is going to take off in 2021 & 2022! Why?? Because of all the Covid-19 investigations that have been going on, and the importance of stem cell therapy when aiding the sick. Anyways, look what I dug up today which is awesome for TSOI - Big Time!
As I read in yesterdays TSOI news they put out, this Dr. Marincola which is now an advisor to TSOI, is world renound; Top Notch in his field. How about this people, HE JUST GOT HIRED YESTERDAY BY, are you sitting down..., GILEAD SCIENCES to head up one of their divisions!! Huge Scientific Immunotherapy Company here in the U.S! ( NASDAQ - $67.23 per share ) The synergies that could exist between TSOI and Dr. Marincola are massive! Why is Dr. Marincola even waisting his time acting as an advisor??? HE SEES THE POTENTIAL IN TSOI!! He probably hangs in the same wheel house as TSOI s Dr. Ichim perhaps. Also, Dr. Santosh Kesari, another TSOI advisor, is top top shelf in stem cell immunotherapy from what i see!
Look :
by Ben Adams | Jan 19, 2021 9:20am
AbbVie and National Institutes of Health (NIH) veteran Francesco Marincola, M.D., will become Gilead’s new head of cell therapy research out of its Kite unit.
He replaces Peter Emtage, Ph.D., who quit the company a few months back for a foray into venture capital work at Versant.
Marincola’s official role as senior vice president and global head of cell therapy research puts him right at the center of an exciting new approach to treating blood and, increasingly, some solid cancers, though it's been fraught with technical difficulties, safety woes and increasing competition.
His role becomes effective Feb. 1, and he will lead all of Kite’s research organization across hematological malignancies and solid tumors. Gilead bought Kite for around $12 billion four years ago, hoping to create a latent to nascent cancer research unit that can build on its infectious disease success.
Kite itself has been ramping up the deals over the years to add better technology and tweaks to its cell therapy platform, while also expanding outside of blood cancers and into the much trickier realm of solid tumors.
Kite is one of a leading pack of companies with approved CAR-T drugs Yescarta and Tecartus, though it is hoping to expand the indications for these therapies while also working on earlier experimental efforts with KITE-718 and KITE-439, both of which are in early trials for solid tumors.
RELATED: Gilead's Kite taps Teneobio to build next-gen CAR-Ts for multiple myeloma
“Franco’s proven track record in oncology and robust research experience that spans the NIH to industry will be critical to the targeting and acceleration of our research efforts in CAR T and beyond,” said Christi Shaw, CEO at Kite.
“As the cell therapy leader, we are thrilled to welcome Franco to our team and are confident that his exceptional skills and expertise will best position our research to discover potentially life-saving therapies for patients in need.”
Marincola joins Kite from Refuge Biotechnologies, where he was president and chief scientific officer, working on its synthetic biology strategies for adoptive cell therapy products and lead programs based on nuclease-deactivated CRISPR circuits.
He is also an NIH-tenured senior investigator in cancer immunotherapy and biomarker research and spent 23 years at the NIH. Previously, he served as a research fellow in immuno-oncology discovery at AbbVie.
“It is an honor to bring my experience to an industry-leading team that is working to make cell therapies with curative intent available to patients,” added Marincola. “I look forward to helping build and diversify our research efforts in support of this mission.”
-----------------------------------------------------------
H U G E I N T E L ! This will not be trading sub penny much longer. Potential 25 X runner here - straight up!! TSOI has way more going for it then CELZ in my opinion, but TSOI has not been discovered yet! Big potential here & zip code changer if you play this right, value the science, and hang on to your TSOI stock for a while.
Cheers
